Physician profile
Patrick D Beaty
NPI 1851480180
$628.01
in general payments reported to CMS, 2019-2025
16 companies · $25.45 in 2025
The $25.45 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $37.42 · 2021: $89.58 · 2022: $102 · 2023: $14.54 · 2025: $25.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $39.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $39.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $159.26 | 2019-2022 | |
| Sanofi Pasteur INC. | $61.22 | 2019-2025 | |
| Allergan, INC. | $50.71 | 2019 | |
| Pfizer INC. | $43.50 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.27 | 2019-2022 | |
| Dynavax Technologies Corporation | $41.29 | 2021-2022 | |
| Gilead Sciences, INC. | $38.40 | 2019 | |
| Lilly USA, LLC | $37.31 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $30.00 | 2019 | |
| Vanda Pharmaceuticals INC. | $29.31 | 2022-2023 | Hetlioz |
| Seqirus USA INC | $26.50 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.75 | 2019 | |
| Amarin Pharma, INC. | $14.08 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.84 | 2019 | |
| Glaxosmithkline, LLC. | $13.15 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Beaty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.